TGFB1 and neoplasm: The combination therapies showed a good safety profile and antitumor activity in both trials.285,286 SAR439459 is a pan-TGFβ ligand-neutralizing antibody, and the combination of SAR439459 and anti-PD1 antibody lead to tumor regression in the MC38 tumor-bearing mice model.287 SAR439459 in combination with the anti-PD1 antibody cemiplimab is now being tested in a phase 1 clinical trials for patients with advanced solid tumors (NCT03192345).